Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

The Dual Role of Neutrophils in Inflammatory Bowel Diseases.

Wéra O, Lancellotti P, Oury C.

J Clin Med. 2016 Dec 17;5(12). pii: E118. doi: 10.3390/jcm5120118. Review.

2.

Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis.

Moćko P, Kawalec P, Smela-Lipińska B, Pilc A.

Arch Med Sci. 2016 Oct 1;12(5):1088-1096. Review.

3.

Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.

Ha C, Kornbluth A.

Gastroenterol Hepatol (N Y). 2014 Dec;10(12):793-800.

4.

The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes.

Fiorino G, Gilardi D, Danese S.

Therap Adv Gastroenterol. 2016 Jul;9(4):503-12. doi: 10.1177/1756283X16647935. Review.

5.

Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab.

Petkau JM, Eksteen B.

Biologics. 2016 Mar 9;10:33-52. doi: 10.2147/BTT.S71679. Review.

6.

Review of vedolizumab for the treatment of ulcerative colitis.

Lau MS, Tsai HH.

World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):107-11. doi: 10.4292/wjgpt.v7.i1.107. Review.

7.

Integrin-based therapeutics: biological basis, clinical use and new drugs.

Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S.

Nat Rev Drug Discov. 2016 Mar;15(3):173-83. doi: 10.1038/nrd.2015.10. Review.

8.

Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.

McLean LP, Cross RK.

Expert Opin Investig Drugs. 2016;25(3):263-73. doi: 10.1517/13543784.2016.1148137. Review.

PMID:
26822204
9.

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.

Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, Gutierrez AM, Ciorba MA.

J Crohns Colitis. 2016 Apr;10(4):402-9. doi: 10.1093/ecco-jcc/jjv226.

PMID:
26681763
10.

Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Hirten R, Sultan K, Thomas A, Bernstein DE.

World J Hepatol. 2015 Nov 28;7(27):2716-28. doi: 10.4254/wjh.v7.i27.2716. Review.

11.

Leukocyte Trafficking to the Small Intestine and Colon.

Habtezion A, Nguyen LP, Hadeiba H, Butcher EC.

Gastroenterology. 2016 Feb;150(2):340-54. doi: 10.1053/j.gastro.2015.10.046. Review.

12.

Biologics in inflammatory bowel disease: what are the data?

Côté-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P.

United European Gastroenterol J. 2015 Oct;3(5):419-28. doi: 10.1177/2050640615590302. Review.

13.

Current stage in inflammatory bowel disease: What is next?

Gómez-Gómez GJ, Masedo Á, Yela C, Martínez-Montiel Mdel P, Casís B.

World J Gastroenterol. 2015 Oct 28;21(40):11282-303. doi: 10.3748/wjg.v21.i40.11282. Review.

14.

Pharmacologic therapy for inflammatory bowel disease refractory to steroids.

Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G.

Clin Exp Gastroenterol. 2015 Aug 17;8:257-69. doi: 10.2147/CEG.S58152. Review.

15.

Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab.

Law JY, Kim DW, Sturgis A, Naina HV.

Clin Med Insights Oncol. 2015 Jul 1;9:61-3. doi: 10.4137/CMO.S27142.

16.

Structural basis of blocking integrin activation and deactivation for anti-inflammation.

Park EJ, Yuki Y, Kiyono H, Shimaoka M.

J Biomed Sci. 2015 Jul 8;22:51. doi: 10.1186/s12929-015-0159-6. Review.

17.

Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.

Jin Y, Lin Y, Lin LJ, Zheng CQ.

World J Gastroenterol. 2015 May 28;21(20):6352-60. doi: 10.3748/wjg.v21.i20.6352. Review.

18.

Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.

Young SA, McCabe KE, Bartakova A, Delaney J, Pizzo DP, Newbury RO, Varner JA, Schlaepfer DD, Stupack DG.

PLoS One. 2015 May 14;10(5):e0120815. doi: 10.1371/journal.pone.0120815.

19.

From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease.

Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM.

Therap Adv Gastroenterol. 2015 May;8(3):143-59. doi: 10.1177/1756283X15576462. Review.

20.

Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys.

Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J.

Eur J Gastroenterol Hepatol. 2015 Jul;27(7):804-12. doi: 10.1097/MEG.0000000000000378. Review.

Items per page

Supplemental Content

Support Center